Cytokinetics abandons ALS drug after failed trial
(Reuters) - Cytokinetics Inc said on Tuesday it would discontinue developing its drug to treat ALS, a fatal neuro-degenerative disorder, after the treatment failed in a late-stage trial.
from Reuters: Health News http://ift.tt/2jaU7zP
http://ift.tt/xePdMM
November 21, 2017
|
Labels:
health,
Reuters: Health News
|
This entry was posted on November 21, 2017
and is filed under
health
,
Reuters: Health News
.
You can follow any responses to this entry through
the RSS 2.0 feed.
or trackback from your own site.